• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Johns Hopkins Arthritis Center

Show Search
Hide Search
  • Disease Information
    • Rheumatoid Arthritis
    • Psoriatic Arthritis
    • Ankylosing Spondylitis
    • Osteoarthritis
    • Gout
    • Osteoporosis
  • Patient Corner
    • Drug Information Sheets
    • Managing Your Arthritis
    • RheumTV – Patient Education Video Library
  • Our Research
    • Patient-Centered Outcomes Research
    • Current Research Studies
    • The Camille Julia Morgan Arthritis Research and Education Fund
  • About Us
    • Appointment Information
    • Contact Us
    • Our Faculty
    • Our Staff
    • Rheumatology Specialty Centers
  • Donate
Home / Arthritis News / Enhanced pathological angiogenesis in mice lacking 3 integrin or 3 and 5 integrins

Enhanced pathological angiogenesis in mice lacking 3 integrin or 3 and 5 integrins

April 13, 2005 By Arthritis Center

Angiogenesis, the growth of new blood vessels, is essential to normal development and to pathological states such as cancer and rheumatoid arthritis (RA). Developing tissues and tumors cannot survive without the nutrients that blood vessels supply. The process of angiogenesis is influenced by growth factors and integrins. Prior research has indicated that the integrins avb3 and avb5 are important in angiogenesis. These studies found that inhibition of avb3 or avb5 suppressed the formation of new blood vessels as well as tumor growth. In this study, Reynolds et al (Nature Medicine 8:27-34, 2002) examined angiogenesis and tumorigenesis in mice lacking b3 or both 3 and b5 integrins.

Methods:

Tumor angiogenesis in b3-deficient mice was examined by injecting b3-null and wild-type mice with murine tumor cells.

Results:

Tumors grew in both mouse lines, with tumor size actually enhanced in the b3-deficient mice. Enhanced tumorigenesis was also found in the mice deficient for both b3 and b5. Additionally, tumors from the b3, b5-deficient mice exhibited a higher density of blood vessels when compared to tumors from the control group. In b3-null cells, vascular endothelial growth factor receptor-2 (VEGFR-2) expression was increased. VEGF is a growth factor that stimulates angiogenesis.

Conclusion:

These data indicate that b3 and b5 integrins are not essential to the development of new blood vessels and demonstrate the need for further research into the mechanisms of integrin inhibitors in anti-angiogenic therapies.

Editorial Comment:

To date, avb3 and avb5 have been thought to be essential for both development and pathological angiogenesis. Angiogenesis is a prominent feature of the synovium in RA and inhibition of avb3/5 are currently in development and/or clinical trial for the treatment of RA. The results demonstrated in this study of b3-null and b3/b5 -null mice are unexpected and totally opposite to what was hypothesized. The authors suggest that perhaps the role of avb3 and avb5 is not the promotion of angiogenesis but rather its negative regulation. They also discuss a number of other possible mechanisms.

At any rate, the results of this study call for a more thorough understanding of the role of integrins in angiogenesis. It would be interesting to evaluate the effect of av3/av5 knockout on the induction of arthritis in susceptible mice. It is remotely possible that b3-null and/or b5-null mice could exhibit enhanced synovial growth and inflammation in response to arthritogenic stimuli, compared to wildtype controls.

Receive the Latest News from Johns Hopkins Rheumatology

Receive the Latest News from Johns Hopkins Rheumatology

Join our mailing list to receive the latest news and updates from Johns Hopkins Rheumatology.

Interested In

You have Successfully Subscribed!

Arthritis Center

Founded in 1998, the Arthritis Center at Johns Hopkins is dedicated to providing quality education to patients and healthcare providers alike.

Use of this Site

All information contained within the Johns Hopkins Arthritis Center website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.

Primary Sidebar

Recent News

Exercise Tips for Arthritis Patients

How Does Exercise Affect my Joints? How Frequently Should I Be Exercising? Should I Lose Weight for Exercise to be

Risks and Benefits of Biologic Medications

Victoria Ruffing, RN, BC, Director of Patient Education at the Johns Hopkins Arthritis Center, shares the risks and benefits of biologic for

How to Manage Rheumatoid Arthritis Flares

Through research, doctors have a clearer understanding of how flares can impact a patient on a personal and emotional level. Dr. Uzma Haque

Complementary & Alternative Medicines for Psoriatic Arthritis

There are many complementary & alternative medicines and practices that have been found to be beneficial in curbing arthritis pain,

I can’t be a runner because I have Rheumatoid Arthritis (RA), right?

Dr. Manno discusses running and Rheumatoid Arthritis. Is it an option for the RA patient?

News Categories

  • Ankylosing Spondylitis News
  • Fibromyalgia News
  • Gout News
  • Lupus News
  • Osteoarthritis News
  • Osteoporosis News
  • Psoriatic Arthritis News
  • Rheumatoid Arthritis News
RheumTV Logo

Rheum.TV is an informational platform created to educate patients living with a rheumatic disease. With over 100 disease education videos produced by the team at Johns Hopkins Rheumatology.

Visit Rheum.TV

Footer

Johns Hopkins Rheumatology

  • Johns Hopkins Rheumatology
  • Johns Hopkins Lupus Center
  • Johns Hopkins Lyme Disease Research Center
  • Johns Hopkins Myositis Center
  • Johns Hopkins Scleroderma Center
  • Johns Hopkins Sjögren’s Syndrome Center
  • Johns Hopkins Vasculitis Center

Connect With Us

  • Facebook
  • Twitter
  • YouTube

Johns Hopkins Medicine

© 2023 Johns Hopkins Arthritis Center
Patient Privacy